OncoMatch/Clinical Trials/NCT06055439
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Is NCT06055439 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CHM-2101 CAR-T cells for neuroendocrine tumors.
Treatment: CHM-2101 CAR-T cells — The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Colorectal Cancer
Gastric Cancer
Biomarker criteria
Required: CDH17 overexpression (CDH17+)
for gastric adenocarcinoma patients only, central laboratory confirmation of CDH17+ tumor expression is required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anti-cancer treatment — locally advanced or metastatic
Have received at least 1 prior line of systemic anti-cancer treatment in the locally advanced or metastatic setting
Cannot have received: CDH17-targeted therapy
Previous treatment with CDH17-targeted therapies
Lab requirements
Blood counts
White blood cell count > 4,000/mm3; ANC ≥ 1,500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 10 g/dL
Kidney function
Creatinine clearance by Cockroft-Gault equation 60 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN; AST ≤ 3 x ULN; ALT ≤ 3 x ULN; Albumin ≥ 3 g/dL
Cardiac function
Left ventricular ejection fraction ≥ 50%
Minimum Laboratory Values for Study Entry Laboratory Assessment Criteria White blood cell count > 4,000/mm3 Absolute neutrophil count (ANC) ≥ 1,500/mm3 Platelets ≥ 100,000/mm3 Hemoglobin ≥ 10 g/dL Total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate amino transferase (AST) ≤ 3 x ULN Alanine transaminase (ALT) ≤ 3 x ULN Creatinine clearance by Cockroft-Gault equation 60 mL/min Oxygen saturation ≥ 92% on room air Albumin ≥ 3 g/dL; Left ventricular ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University · Atlanta, Georgia
- University of Chicago · Chicago, Illinois
- University of Pennsylvania · Philadelphia, Pennsylvania
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify